Flux Sampling Suggests Metabolic Signatures of High Antibody‐Producing CHO Cells
Biotechnology and Bioengineering · 2025-07 · 122 (7) · 1898-1913
DOI: 10.1002/bit.28982 ↗At a glance
Journal article in Biotechnology and Bioengineering, published online on 2025-04-11. Written by Kate E Meeson and 9 co-authors. Institution: Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. Major MEDLINE topics: Antibodies, Monoclonal, Recombinant Proteins, Models, Biological, Metabolic Flux Analysis. Cited 8 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY 4.0). Funded by: The authors acknowledge financial support from a Prosperity Partnership grant (EP/V038095/1) funded by EPSRC, BBSRC, and FUJIFILM Diosynth Biotechnologies. Thi…, Engineering and Physical Sciences Research Council.
Abstract (original language)
Chinese hamster ovary (CHO) cells remain the industry standard for producing numerous therapeutic proteins, particularly monoclonal antibodies (mAbs). However, achieving higher recombinant protein titers remains an ongoing challenge and a fundamental understanding of the cellular mechanism driving improved bioprocess performance remains elusive. To directly address these challenges and achieve substantial improvements, a more in‐depth understanding of cellular function within a bioprocess environment may be required. Over the past decade, significant advancements have been made in the building of genome‐scale metabolic models (GEMs) for CHO cells, bridging the gap between high information content 'omics data and the ability to perform in silico phenotypic predictions. Here, time‐course transcriptomics has been employed to constrain culture phase‐specific GEMs, representing the early exponential, late exponential, and stationary/death phases of CHO cell fed‐batch bioreactor culture. Temporal bioprocess data, including metabolite uptake and secretion rates, as well as growth and productivity, has been used to validate flux sampling results. Additionally, high mAb‐producing solutions have been identified and the metabolic signatures associated with improved mAb production have been hypothesized. Finally, constraint‐based modeling has been utilized to infer specific amino acids, cysteine, histidine, leucine, isoleucine, asparagine, and serine, which could drive increased mAb production and guide optimal media and feed formulations.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
- Manchester Institute of Biotechnology, University of Manchester, Manchester, UK.
- EdinOmics, RRID:SCR_021838, Centre for Engineering Biology, School of Biological Sciences, University of Edinburgh, Edinburgh, UK.
- FUJIFILM Diosynth Biotechnologies, Billingham, UK.
ORCID profiles: Kate E Meeson, Joanne Watson, Susan Rosser, Andrew Pitt, Tessa Moses, Leon Pybus, Magnus Rattray, Alan J Dickson
Funding
- The authors acknowledge financial support from a Prosperity Partnership grant (EP/V038095/1) funded by EPSRC, BBSRC, and FUJIFILM Diosynth Biotechnologies. Thi…
- Engineering and Physical Sciences Research Council
Cite
APA
Meeson, K. E., Watson, J., Rosser, S., Hawke, E., Pitt, A., Moses, T., Pybus, L., Rattray, M., Dickson, A. J., & Schwartz, J. M. (2025). Flux Sampling Suggests Metabolic Signatures of High Antibody‐Producing CHO Cells. Biotechnology and Bioengineering, 122(7), 1898-1913. https://doi.org/10.1002/bit.28982
Vancouver
Meeson KE, Watson J, Rosser S, Hawke E, Pitt A, Moses T, et al. Flux Sampling Suggests Metabolic Signatures of High Antibody‐Producing CHO Cells. Biotechnology and Bioengineering. 2025;122(7):1898-1913. doi:10.1002/bit.28982
BibTeX
@article{Meeson2025,
author = {Meeson, Kate E and Watson, Joanne and Rosser, Susan and Hawke, Ellie and Pitt, Andrew and Moses, Tessa and Pybus, Leon and Rattray, Magnus and Dickson, Alan J and Schwartz, Jean-Marc},
title = {Flux Sampling Suggests Metabolic Signatures of High Antibody‐Producing CHO Cells},
journal = {Biotechnology and Bioengineering},
year = {2025},
volume = {122},
number = {7},
pages = {1898--1913},
doi = {10.1002/bit.28982}
}
EUVIMED